Abstract: The application relates to a process for drying a composition comprising an alkali metal salt of a compound of general formula (I) R1R2N—CHR3—COOM or formula (II) R1R2N—CHR3CHR3—COOM, in particular N,N-dimethyl glycinate salt, and the use thereof.

Abstract: Processes are disclosed for the synthesis of an ?-amino acid or ?-amino acid derivative, from a starting compound or substrate having a carbonyl functional group (C?O), with hydroxy-substituted carbon atoms at alpha (?) and beta (?) positions, relative to the carbonyl functional group. According a particular embodiment, an ?-, ?-dihydroxy carboxylic acid or carboxylate is dehydrated to form a dicarbonyl intermediate by transformation of the ?-hydroxy group to a second carbonyl group (adjacent a carbonyl group of the starting compound) and removal of the ?-hydroxy group. The dicarbonyl intermediate is optionally cracked to form a second, in this case cracked, dicarbonyl intermediate having fewer carbon atoms relative to the dicarbonyl intermediate but preserving the first and second carbonyl groups. Either or both of the dicarbonyl intermediate and the cracked dicarbonyl intermediate may be aminated to convert the second carbonyl group to an amino (—NH2) group, for producing the corresponding ?-amino acid(s).

Abstract: Glycine is an organic compound that can be used in the making of a synthetic acid that obviates all the drawbacks of strong acids such as hydrochloric acid. The new compound is made by dissolving glycine in water, in a weight ratio of approximately 1:1 to 1:1.5. The solution is mixed until the glycine is essentially fully dissolved in the water. Once dissolution is complete, hydrogen chloride gas is dissolved in the solution to produce the new compound, which can be referred to as hydrogen glycine. Also disclosed is a method for adjusting the pH of a fluid, the method comprising adding an effective amount of a solution to the fluid for adjusting the pH thereof to a desired level, wherein the solution is prepared by mixing glycine in water to form a glycine solution; and adding hydrogen chloride to the glycine solution.

Abstract: The present invention relates to a novel chiral phase-transfer catalyst, and a method for preparing an alpha-amino acid by using the same. According to the present invention, an alpha-amino acid of high optical purity could be synthesized in a high yield under an easy industrially applicable reaction condition by using a novel cinchona alkaloid compound as a chiral phase-transfer catalyst, and thus the present invention can be used as a key technique of the asymmetric alpha-amino acid synthesis and preparation field.

Abstract: A process for the specific isotopic labeling of an amino acid selected from Valine (Val), Leucine (Leu), and Isoleucine (Ile), in proteins and biomolecular assemblies by introducing, in a medium containing bacteria overexpressing a protein, an acetolactate derivative of Formula I of the application.

Abstract: Process for the preparation of alkali metal salts of glycine or of racemic ?-amino acids of the general formula (I) R1—CH(NH2)—COOH??(I) in which R1 is selected from hydrogen, CH3, C2H5, CH(CH3)2, (CH2)2COOH and CH2OH, wherein an alkali metal salt of the corresponding ?-ketocarboxylic acid or glyoxalic acid is reacted in the presence of at least one heterogeneous catalyst, which comprises at least one transition metal, in the presence of hydrogen with at least one nitrogen compound at temperatures in the range from 50 to 200° C., where the nitrogen compound is selected from primary and secondary amines and ammonia.

Abstract: A method for treating a contaminated alkaline amino acid salt solution is provided. First, carbon dioxide is introduced into the amino acid salt solution, with the result that carbonate or carbonate salts is or are precipitated, these being filtered off. The remaining filtrate is then cooled, amino acid or amino acid salts being crystallized out and likewise being filtered off. The amino acid or amino acid salt is then dissolved again, with the result that a treated amino acid salt solution is recovered.

Abstract: Improved processes for making an N-acyl amino acid salt from a fatty alkyl ester or a polyol ester are disclosed. Each process uses a polyol selected from glycerin or propylene glycol in an amount effective to keep the reaction mixture fluid until conversion to the N-acyl amino acid salt reaches the desired level of completion. In one process, a fatty alkyl ester reacts with an amino acid salt in the presence of glycerin or propylene glycol to produce an N-acyl amino acid salt. In another process, a polyol ester reacts with the amino acid salt in the presence of added glycerin or propylene glycol to produce the N-acyl amino acid salt. We surprisingly found that an effective amount of glycerin or propylene glycol minimizes or eliminates reaction mixture solidification or foaming, reduces color, and minimizes the level of di- and tripeptide by-products. In a related process, water is added when conversion of the amino acid salt to the N-acyl amino acid salt is in the range of 50 to 90 mole %.

Abstract: The present invention relates to a method of separating betaine and at least one other component from a sugar beet based fermentation solution. The invention is based on the use of a combination of SAC resins and WAC resins in a specific order and in specified proportions in a chromatographic SMB separation system. The chromatographic separation system is preferably a single integrated SMB system comprising both SAC and WAC resin beds.

Abstract: Glycine is an organic compound that can be used in the making of a synthetic acid that obviates all the drawbacks of strong acids such as hydrochloric acid. The new compound is made by dissolving glycine in water, in a weight ratio of approximately 1:1 to 1:1.5. The solution is mixed until the glycine is essentially fully dissolved in the water. Once dissolution is complete, hydrogen chloride gas is dissolved in the solution to produce the new compound, which can be referred to as hydrogen glycine. A method of taming an acid includes adding the solution of hydrogen glycine to the acid in an effective amount for substantially preventing corrosion and fuming during an application of a mixture thereof.

Abstract: The problem to be solved by the present invention is to ea lily and efficiently produce an amino acid having 2 to 7 carbon atoms as a high-purity solid without complicated operation, which is useful as a synthetic intermediate for medicines or agrochemicals. The present invention is characterized in comprising a step of precipitating solid amino acid with high purity. In the present invention, the by-produced salt composed of the sulfonic acid and the amine was removed to the mother liquor by reacting an amine with a sulfonic acid salt of amino acid in an aprotic polar solvent, or by reacting a sulfonic acid with an amine salt of amino acid in an aprotic polar solvent. The sulfonic acid salt of amino acid, for example, may be produced by reacting a N-(tert-butoxycarbonyl) amino acid with a sulfonic acid, or by reacting an amino acid tert-butyl ester with a sulfonic acid.

Abstract: Provided herein are processes for the preparation of N-acylated amines. In particular, the processes comprise contacting an amine with an acid comprising a carboxylic acid group to form the N-acylated amine.

Abstract: Glycine is an organic compound that can be used in the making of a synthetic acid that obviates all the drawbacks of strong acids such as hydrochloric acid. The new compound is made by dissolving glycine in water, in a weight ratio of approximately 1:1 to 1:1.5. The solution is mixed until the glycine is essentially fully dissolved in the water. Once dissolution is complete, hydrogen chloride gas is dissolved in the solution to produce the new compound, which can be referred to as hydrogen glycine.

Abstract: The present invention relates to a method of removing an Fmoc group, including a step of mixing a compound represented by the formula (I): HS-L-COOH??(I) wherein L is a C1-8 alkylene group optionally having substituent(s), an amino group-containing compound protected by an Fmoc group, and a base to give a reaction mixture containing a compound represented by the formula (II): Fm-S-L-COOH??(II) wherein Fm is a 9-fluorenylmethyl group, and L is as mentioned above, and an amino group-containing compound, and a step of removing the compound represented by the formula (II) by washing the obtained reaction mixture with a basic aqueous solution. According to the present invention, a removal method of Fmoc group, which can remove a dibenzofulvene derivative as a byproduct with ease, can be provided.

Abstract: Processes for lightening keratinic fibers are provided. In an exemplary process a ready-to-use lightening composition is produced by, immediately prior to application, combining a composition (A) comprising an alkalizing agent, a composition (B) comprising an oxidizing agent, and a composition (C) comprising a peroxo salt, and then mixing. The ready-to-use lightening composition is deployed from a foam dispensing vessel and distributed onto the fibers. The ready-to-use lightening composition is left on the fibers for a period of about 1 to about 60 min. and is washed out of the fibers.

Abstract: Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.

Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.

Abstract: Hydrophilic, biocidal coating compositions and methods to make and use the compositions are disclosed. The coatings include compounds with quaternary amine polyethylene glycol groups and polyaminoalkyl biguanide groups as substituents. The compounds when incorporated in paints provide hydrophilic, self-cleaning and biocidal property to the coating.

Abstract: The present invention relates to a method for continuously preparing a betaine aqueous solution, including the reaction of an amine with an ?-halocarboxylic acid, in the presence of water and a base. Said method is characterized in that it is carried out in a device consisting of at least two consecutive reactors (R1) and (R2), the reactor (R2) being a tubular reactor.

Abstract: A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto.

Abstract: The present invention provides a compound of the following formula (I) below. This compound (I) can be produced by reacting a 2,2?-dimethylene bromide-1,1?-binaphthyl derivative, which can be produced by a relatively small number of processes, with an easily available secondary amine. This compound (I) is useful as a chiral phase-transfer catalyst.

Abstract: The invention provides a pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier.

Abstract: The present invention provides a compound of the following formula (I) below. This compound (I) can be produced by reacting a 2,2?-dimethylene bromide-1,1?-binaphthyl derivative, which can be produced by a relatively small number of processes, with an easily available secondary amine. This compound (I) is useful as a chiral phase-transfer catalyst.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy.

Abstract: Disclosed are betaine and a Lycium chinensis leaf extract and a mixture thereof which are preventive and therapeutic of obesity, and uses thereof. They are found to have prophylactic and therapeutic effects on obesity and obesity-induced metabolic syndrome as evaluated for reductive activity against weight, body fat, total cholesterol, triglyceride, and LDL in humans and in mice. Thus, they can be used as active ingredients in pharmaceutical or health functional food compositions for the prevention and treatment of obesity or obesity-induced metabolic syndrome.

Abstract: Provided herein are polypeptides having ketol-aid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.

Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryphtophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.

Abstract: Glycine is an organic compound that can be used in the making of a synthetic acid that obviates all the drawbacks of strong acids such as hydrochloric acid. The new compound is made by dissolving glycine in water, in a weight ratio of approximately 1:1 to 1:1.5. The solution is mixed until the glycine is essentially fully dissolved in the water. Once dissolution is complete, hydrogen chloride gas is dissolved in the solution to produce the new compound, which can be referred to as hydrogen glycine.

Abstract: The present disclosure relates to an ASD genetically engineered model carrying a deletion of Shank2 gene and having reduced NMDA receptor function. According to the present disclosure, genetically engineered mice that show the clinical features of ASD due to the deletion of the Shank2 gene can be obtained, and the genetically engineered mice can be effectively used to screen candidate therapeutic agents.

Abstract: A method for producing amino acid chelate compounds, characterized in that metal oxides and/or metal carbonates and/or metal sulfates and/or metal chlorides and/or metal hydroxides in solid form are activated mechanically and then the activated metal oxides and/or metal carbonates and/or metal hydroxides and/or metal sulfates and/or metal chlorides are brought together with amino acids in solid form and converted to amino acid chelate compounds in a solid-state reaction.

Abstract: Provided herein are novel alkynyl and azide containing amino acids; kits containing these amino acids; peptides containing these amino acids; peptide macrocycles whose secondary structures are stabilized with linkers containing triazoles synthesized by reacting the side chains of the alkynyl and azide containing amino acids; and methods of making and using the alkynyl and azide containing amino acids, kits, peptides, triazole containing linkers, and peptide macrocycles.

Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.

Abstract: This disclosure describes draw solution compositions for FO processes which increase the available membrane area for permeation and are also amenable to reconcentration with standard techniques, such as membrane filtration and evaporative technologies. The composition are comprised of a water soluble draw solute having surface active properties, i.e., a surfactant.

Abstract: A packing material for liquid chromatography capable of separating and purifying, or collecting and recovering, a biopolymer such as a protein or a peptide by adsorption and desorption by a pH change without being influenced by the isoelectric point of the protein or by the salt concentration in a solvent in which the biopolymer such as the protein is dissolved. Separation and purification, or collection and recovery, of a biopolymer, is carried out by liquid chromatography by means of a packing material for liquid chromatography comprising a base matrix and a ligand immobilized to the base matrix, wherein the base matrix is a hydrophilic base matrix having alcoholic hydroxy groups on its surface, the ligand is at least one ligand selected from the group consisting of an ?-amino acid which is immobilized to the base matrix by an amide bond or an urethane bond via the amino group contained in the ?-amino acid.

Abstract: Salts of mineral nutrients stabilized with amino acids and/or ammonium salt, product and food supplement in which they are included and procedures of obtention, where the salts are obtained with anions of organic acids or inorganic anions and metallic cations associated with amino acids and/or ammonium salt, in which the invention introduces its general structure: {[Ac]n?·Men+?n[Amino acid and/or ammonium salt]}·xH2O Where ? represents a covalent dative bond, These new compounds have better taste and more solubility in water, making them more bioavailable.

Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.

Abstract: An absorption medium for removing acid gases from a fluid stream comprises an aqueous solution (A) of an alkali metal salt of an N,N-di-C1-C4-alkylaminocarboxylic acid and (B) N-hydroxyethylpiperazine. The absorption medium has a low vapor pressure and an increased resistance to oxygen. Preferred fluid streams are combustion exhaust gases or biogas.

Abstract: An industrially advantageous method for producing an optically active 1,2-bis(dialkylphosphino)benzene derivative of the present invention is provided. The method is characterized in that a phosphine-borane compound represented by the following general formula (1) is subjected to a deboronation reaction, followed by lithiation, then the reaction product is subjected to reaction with an alkyldihalogenophosphine represented by RaPX?2, and thereafter the reaction product is subjected to reaction with a Grignard reagent represented by RbMgX? to produce an optically active 1,2-bis(dialkylphosphino)benzene derivative (A). R1 and R2 respectively represent an alkyl group having 1 to 8 carbon atoms, and the number of carbon atoms is different between R1 and R2. Ra is either R1 or R2 and Rb is the other of R1 and R2. X, X?, and X? each represent a halogen atom.

Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

Abstract: Process for the preparation of racemic ?-amino acids or of glycine, wherein the corresponding ?-hydroxycarboxylic acid, selected from hydroxyacetic acid, lactic acid, malic acid, ?-hydroxyglutamic acid, isocitric acid, tartronic acid and tartaric acid, or at least one salt of the corresponding ?-hydroxycarboxylic acid is reacted in the presence of at least one heterogeneous catalyst which comprises at least one transition metal, in the presence of hydrogen with at least one nitrogen compound (c), where the nitrogen compound (c) is selected from primary and secondary amines and ammonia.

Abstract: This invention is directed a process for preparation of a carboxylic acid salt by dehydrogenation of a primary alcohol. The invention is also directed to a catalyst for dehydrogenating primary alcohols. In one embodiment, for example, the catalyst comprises a metal support (preferably a metal sponge support) having a copper-containing coating at the surface thereof. In another embodiment, the catalyst comprises a metal selected from the group consisting of zinc, cobalt, iron, tin and combinations thereof having a copper-containing coating at the surface thereof.

Abstract: By selecting one or more deodorizing agents from among glycine, cysteine and glycylglycine, and incorporating the selected deodorizing agent(s) and a surfactant, the toxicity of the surfactant to men and beasts is controlled without inhibiting the antibacterial actions that the surfactant has inherently. Glycine, cysteine, and glycylglycine each have a strong deodorizing action. The invention causes antibacterial deodorants to further have a deodorizing action by using such deodorizing agents. Moreover, the invention increases the permeating ability, thereby enhancing both the antibacterial action and the deodorizing action by subjecting water to treatment for fragmenting a cluster of the water and then adding the resulting active water as a diluent, or by preparing the diluent by incorporating alcohol with the active water.

Abstract: Disclosed are compositions and methods of preparing compositions of active herbicidal ingredients. Also disclosed are methods of using the compositions described herein to improve herbicide delivery and efficacy, enhance herbicidal penetration, reduce herbicide volatility and drift, diminish environmental damage from herbicides, decrease water solubility and volatility of herbicides, and introduce additional biological function to herbicides.

Abstract: A thin film composition for oral administration that adheres to and dissolves in a mouth of a user, wherein the thin film is a single layered water-soluble solid comprising at least one D-amino acid contained in a plurality of hydrophobic carriers dispersed throughout the thin film. The hydrophobic carriers comprise oil and the composition further comprises a phospholipid, an emulsifier, and a water soluble polymer. The preferred D-amino acids are D-leucine, D-tryptophan, D-methionine, and D-tyrosine. A method of reducing dental plaque in a subject entails placing the thin film composition contemplated herein into a mouth of the subject.

Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.

Abstract: The invention relates to the use of solid betaine for de-icing and/or preventing slipperiness. The solid betaine comprises at least one non-betaine compound affecting water and/or moisture movement in said solid betaine. The invention further relates to a process for the manufacture of solid betaine. A suspension comprising betaine crystals is prepared from a feed liquid and the betaine crystals are separated and washed. The amount of wash liquid is adjusted in order to leave 0.5 to 10 w-% of at least one non-betaine compound in said solid betaine.

Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.

Abstract: The present invention relates to a method for preparing optically active N-methylamino acids and/or optically active N-methylamino acid amides by subjecting the cells or treatment products of a microorganism belonging to the Mycoplana genus to the hydrolysis with N-methylamino acid amide to give an optically active N-methylamino acid and an optically active N-methylamino acid amide. According to the present invention, optically active N-methylamino acids and optically active N-methylamino acid amides useful as the raw material of pharmaceuticals can be stereoselectively obtained with good efficiency.

Abstract: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.